Wugen, Inc., a clinical-stage U.S. biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological and solid tumor malignancies, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback